quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·28d
PRRelease
NovoCure Limited logo

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

NVCR· NovoCure Limited
Health Care
Original source

Companies

  • NVCR
    NovoCure Limited
    Health Care

Recent analyst ratings

  • Jul 25UpdateWells Fargo$14.50
  • Jul 8UpdateLadenburg Thalmann$30.00
  • Dec 2UpdateEvercore ISI$30.00
  • Oct 16UpdateH.C. Wainwright$30.00
  • Nov 20UpdateJP Morgan$15.00
  • Aug 28UpdateH.C. Wainwright$25.00

Related

  • SEC3d
    SEC Form DEFA14A filed by NovoCure Limited
  • SEC3d
    SEC Form DEF 14A filed by NovoCure Limited
  • SEC14d
    NovoCure Limited filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
  • PR22d
    Novocure to Report First Quarter 2026 Financial Results
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by NovoCure Limited
  • SEC28d
    NovoCure Limited filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
  • INSIDER49d
    Former Chief Medical Officer Leupin Nicolas sold $14,636 worth of Ordinary Shares (1,100 units at $13.31), decreasing direct ownership by 1% to 102,979 units (SEC Form 4)
  • INSIDER49d
    Former Chief Executive Officer Cordova Ashley covered exercise/tax liability with 17,638 units of Ordinary Shares, decreasing direct ownership by 4% to 422,570 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022